CR11744A - Formulacion liquida para deferiprona con gusto agradable al paladar - Google Patents

Formulacion liquida para deferiprona con gusto agradable al paladar

Info

Publication number
CR11744A
CR11744A CR11744A CR11744A CR11744A CR 11744 A CR11744 A CR 11744A CR 11744 A CR11744 A CR 11744A CR 11744 A CR11744 A CR 11744A CR 11744 A CR11744 A CR 11744A
Authority
CR
Costa Rica
Prior art keywords
deferiprone
palate
liquid formulation
nice taste
taste
Prior art date
Application number
CR11744A
Other languages
English (en)
Inventor
Michael Spino
Anita Hui
Cihua Yang
Mohammed N Kabir
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of CR11744A publication Critical patent/CR11744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Abstract

Una formulación farmacéutica oral líquida que comprende deferiprona y una composición de enmascaramiento del gusto, dicha composición de enmascaramiento de gusto comprende una cantidad efectiva de edulcorante.
CR11744A 2008-04-25 2010-10-20 Formulacion liquida para deferiprona con gusto agradable al paladar CR11744A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2008/000784 WO2009129592A1 (en) 2008-04-25 2008-04-25 Liquid formulation for deferiprone with palatable taste

Publications (1)

Publication Number Publication Date
CR11744A true CR11744A (es) 2011-01-10

Family

ID=41216357

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11744A CR11744A (es) 2008-04-25 2010-10-20 Formulacion liquida para deferiprona con gusto agradable al paladar

Country Status (25)

Country Link
US (1) US8703156B2 (es)
EP (1) EP2268282B1 (es)
KR (1) KR101490721B1 (es)
CN (1) CN102014904B (es)
AP (1) AP2010005454A0 (es)
AU (1) AU2008355464C1 (es)
BR (1) BRPI0822206B8 (es)
CA (1) CA2722393A1 (es)
CR (1) CR11744A (es)
CY (1) CY1116146T1 (es)
DK (1) DK2268282T3 (es)
EA (1) EA022751B1 (es)
ES (1) ES2539414T3 (es)
HK (1) HK1152871A1 (es)
HR (1) HRP20150083T1 (es)
IL (1) IL208876A (es)
MX (1) MX2010011701A (es)
NZ (1) NZ588602A (es)
PL (1) PL2268282T3 (es)
PT (1) PT2268282E (es)
RS (1) RS53689B1 (es)
SI (1) SI2268282T1 (es)
UA (1) UA102254C2 (es)
WO (1) WO2009129592A1 (es)
ZA (1) ZA201008374B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
PL2448922T3 (pl) 2009-07-03 2015-02-27 Apotex Tech Inc Fluorowane pochodne 3-hydroksypirydyn-4-onów
CN104955482A (zh) 2012-11-12 2015-09-30 希普拉有限公司 包含地拉罗司和去铁酮的固定剂量的药物组合物
WO2017199073A1 (en) * 2016-05-18 2017-11-23 Karimian, Khashayar Effervescent deferiprone tabelt
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
SG11202003153TA (en) 2017-10-25 2020-05-28 Chiesi Farm Spa Delayed release deferiprone tablets and methods of using the same
MX2021010945A (es) * 2019-03-14 2021-10-13 Neuroenergy Ventures Inc Formula que enmascara el sabor para compuestos de cuerpos cetonicos.
NL2024161B1 (en) * 2019-11-05 2021-07-20 Mperium B V Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
WO2024023785A1 (en) 2022-07-29 2024-02-01 Berlia Sushma Paul A stable pharmaceutical oral liquid formulation of an antispasmodic agent

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
USRE25831E (en) 1962-12-20 1965-08-03 Method for dyeing acrylonitrile polymer fibers
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
USRE34313E (en) 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
DE3826846A1 (de) 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
NO941358L (no) 1993-04-16 1994-10-17 Mcneil Ppc Inc Vandig farmasöytisk suspensjon og fremgangsmåte for fremstilling derav
CA2181463A1 (en) 1994-01-31 1995-08-03 Fu-Ning Fung Method of synthesizing gamma pyrones
EP0754039A4 (en) * 1994-04-08 2002-07-17 Procter & Gamble METHODS OF USING IRON-CONTAINING CHELATES TO REDUCE MAMMALIAN FREE RADICAL DAMAGES
WO1996003976A1 (en) 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6576677B1 (en) 1998-08-28 2003-06-10 Eisai Co., Ltd. Medicinal compositions with relieved bitterness
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2004535370A (ja) * 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
AU2003222513A1 (en) 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
WO2004006856A2 (en) 2002-07-12 2004-01-22 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
WO2004041151A2 (en) 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
DE10336497B4 (de) 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
CA2568134A1 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
PT1991225E (pt) 2006-02-22 2014-02-13 Apotex Technologies Inc Utilização de deferiprona e métodos para tratar e/ou prevenir a ataxia de friedreich resultante dum incorreto tratamento intracelular do ferro
US8026261B2 (en) 2007-03-28 2011-09-27 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
PL2268282T3 (pl) 2015-04-30
US20110039897A1 (en) 2011-02-17
EA022751B1 (ru) 2016-02-29
PT2268282E (pt) 2015-02-05
HRP20150083T1 (hr) 2015-03-13
AU2008355464C1 (en) 2014-11-20
WO2009129592A1 (en) 2009-10-29
DK2268282T3 (en) 2014-11-24
CN102014904A (zh) 2011-04-13
BRPI0822206B1 (pt) 2019-03-19
AU2008355464B2 (en) 2014-04-10
AU2008355464A1 (en) 2009-10-29
IL208876A (en) 2015-02-26
ZA201008374B (en) 2012-01-25
CA2722393A1 (en) 2009-10-29
NZ588602A (en) 2012-08-31
EP2268282B1 (en) 2014-10-29
EP2268282A1 (en) 2011-01-05
KR101490721B1 (ko) 2015-02-06
CN102014904B (zh) 2013-02-06
AP2010005454A0 (en) 2010-12-31
BRPI0822206A2 (pt) 2015-06-23
UA102254C2 (ru) 2013-06-25
EP2268282A4 (en) 2011-06-22
ES2539414T3 (es) 2015-06-30
BRPI0822206B8 (pt) 2021-05-25
US8703156B2 (en) 2014-04-22
EA201071235A1 (ru) 2011-06-30
HK1152871A1 (en) 2012-03-16
CY1116146T1 (el) 2017-02-08
IL208876A0 (en) 2011-01-31
RS53689B1 (en) 2015-04-30
KR20100135316A (ko) 2010-12-24
MX2010011701A (es) 2010-12-06
SI2268282T1 (sl) 2015-01-30

Similar Documents

Publication Publication Date Title
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
ECSP10010295A (es) Formulacion de anticuerpo
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
AR069875A1 (es) Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
CU20100230A7 (es) Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
ECSP099776A (es) Moduladores de la gamma secretasa
AR082215A1 (es) Composicion farmaceutica agradable al paladar
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
ECSP088889A (es) Forma nueva de administración de racecadotril
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
ECSP12011618A (es) Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
BRPI0920878A2 (pt) inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.
WO2010099510A3 (en) Amino acid-based compounds, their methods of use, and methods of screening
CO6720980A2 (es) Composiciones bucales
EA200901591A1 (ru) Фармацевтические композиции производных s-алкилизотиоурония с маскированным вкусом
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
UY32197A (es) Sinergismo antibiotico
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)